St. John’s wort and drug interactions
This article was originally published in The Tan Sheet
Executive Summary
Cancer patients, oncologists should cooperate to "develop a plan regarding which CAM practices to pursue and which to put aside altogether," NCCAM Director Stephen Straus, MD, and staff clinician Patrick Mansky, MD, advise in Aug. 21 Journal of the National Cancer Institute. "No matter how beneficial some approaches may appear to be, they are not all safe," NIH officials stress in editorial accompanying study on use of St. John's wort by cancer patients. Conducted by a Dutch research group, randomized, cross-over study of five cancer patients found anti-tumor activity of cancer drug irinotecan is negatively affected by concurrent use of St. John's wort. Findings were released at the American Association for Cancer Research annual meeting in April (1"The Tan Sheet" April 15, 2002, p. 13)...
You may also be interested in...
St. John’s Wort Multi-Center Trial In Mild Depression Underway
A multi-center clinical trial on St. John's wort in mild depression is underway with $4 mil. in funding from three National Institutes of Health divisions, according to the National Center for Complementary and Alternative Medicine
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.